Stabilized Egg Protein Formulations for Consistent Oral Immunotherapy Dosing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for egg allergy, such as strict avoidance diets, are challenging due to the difficulty in interpreting food labels and the presence of hidden allergens, and there are no effective oral immunotherapy options, leading to unpredictable reactions and inconsistent allergen dosing.

Innovation Solution

Egg protein formulations stabilized with characterized levels of ovomucoid, ovalbumin, and lysozyme proteins, combined with diluents, lubricants, and filling agents, providing consistent dosing and improved shelf life for oral immunotherapy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If strict avoidance diets are used to treat egg allergy, then allergic reactions are prevented, but quality of life deteriorates due to difficulty in interpreting food labels and compliance challenges

Engineering Contradiction:

Improveprevention of allergic reactionsVSAvoidcompliance with avoidance diet

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent applies preliminary action by administering controlled doses of egg protein formulations before exposure to potential allergens in food. This proactive desensitization approach builds immune tolerance in advance, allowing patients to eventually consume egg-containing foods without strict avoidance, thereby improving compliance while maintaining reliability of allergy prevention

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses egg protein formulations as an intermediary substance that mediates between the allergen (egg protein in food) and the patient's immune system. By controlling the dosage and presentation of the allergen through standardized formulations, the immune system is gradually trained to tolerate it, transforming the harmful direct exposure into a controlled therapeutic process

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of operation

If oral immunotherapy with egg protein is implemented, then desensitization and quality of life improvement are achieved, but unpredictable allergic reactions and inconsistent dosing may occur

Engineering Contradiction:

Improvequality of lifeVSAvoidpredictability of allergic reactions

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent applies parameter changes by precisely controlling the concentration, purity, and composition parameters of egg protein formulations. By standardizing these parameters across different batches and doses, the therapy achieves consistent and predictable immunological responses, eliminating the unpredictability associated with natural egg products while maintaining the ability to induce desensitization

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent replaces the mechanical/physical variability of natural egg products with a standardized pharmaceutical formulation system. Instead of relying on the inconsistent composition of natural eggs, the invention uses purified and characterized egg protein formulations with controlled delivery mechanisms, substituting natural variability with engineered consistency

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Quantity of substance

If natural egg products are used for immunotherapy, then allergen exposure is provided, but dosing consistency and shelf life are insufficient

Engineering Contradiction:

Improveallergen exposureVSAvoiddosing consistency

Core Design Contradiction:

Quantity of substanceVSManufacturing precision

Solution Approach 1:

The patent applies extraction by isolating and purifying specific egg proteins (ovomucoid, ovalbumin, lysozyme) from natural egg products. This separation allows for precise control of allergen content and elimination of variable components found in natural eggs, achieving consistent dosing while maintaining adequate allergen exposure for immunotherapy

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses composite materials by formulating egg protein formulations with stabilizing agents and excipients that enhance shelf life and dosing consistency. The composite formulation combines purified egg proteins with protective materials that maintain stability during storage and ensure precise dosing, overcoming the limitations of natural egg products

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS12383584B2Egg protein formulations and methods of manufacture thereof

Publication Date: 2025.08.12 SOCIETE DES PRODUITS NESTLE SA

AI summary

The present technology relates generally to formulations comprising egg white protein, methods of manufacturing egg protein formulations and uses for egg protein formulations. In particular, several embodiments are directed to egg protein formulations for oral administration in immunotherapy of subjects affected by egg allergies.